BJU International
Author:
Keywords:
Science & Technology, Life Sciences & Biomedicine, Urology & Nephrology, renal cell carcinoma, RCC, sunitinib, prognostic markers, C-reactive protein, INTERFERON-ALPHA, CANCER STATISTICS, TARGETED THERAPY, DOUBLE-BLIND, INTERLEUKIN-6, SURVIVAL, REGRESSION, LEVEL, Adult, Aged, Antineoplastic Agents, Belgium, C-Reactive Protein, Carcinoma, Renal Cell, Disease-Free Survival, Female, France, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Retrospective Studies, Sunitinib, Treatment Outcome, 1103 Clinical Sciences, 3202 Clinical sciences, 3211 Oncology and carcinogenesis
Abstract:
To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib.